In classical Hodgkin lymphoma the malignant Hodgkin/ Reed-Sternberg (HRS) cells characteristically constitute only a small minority of the tumour load. Their origin has been debated for decades, but on the basis of rearrangement and somatic hypermutations of their immunoglubulin (Ig) genes, HRS cells are now ascribed to the B-cell lineage. Nevertheless, phenotypically HRS cells have lost their B cell identity: they usually lack common B cell-specific surface markers such as CD19 and CD79a as well as Ig gene transcripts. Here we demonstrate that Ig promoters as well as both intronic and 3' enhancer sequences are transcriptionally inactive in HRS cell lines. This inactivity correlates with either reduced levels or even a complete lack of several B cellspecific transcription factors required for their expression: Oct-2, OBF-1, PU.1, E47/E12, PAX-5 and EBF. Moreover, we demonstrate that PU.1 and PAX-5 are significantly down-regulated in HRS cells in pathological specimens from primary tumour tissues. However, forced expression of these transcription factors can activate regulatory sequences of silenced B cell marker genes, and in one instance also transcription from a silenced endogenous locus. Thus, HRS cells are dedifferentiated B cells with global down-regulation of B cell-specific genes.
Introduction
Classical Hodgkin lymphoma (HL) is one of the most frequent malignant lymphomas in Europe and North America. Morphologically, it is characterized by the presence of multinucleated Reed-Sternberg cells and mononuclear Hodgkin cells in a stromal background including non-malignant lymphocytes, plasma cells, histiocytes and eosinophils. The malignant Hodgkin/ Reed-Sternberg (HRS) cells in HL characteristically constitute only a minority of tissue cells, often corresponding to less than one per cent of the total tumour load.
The cellular origin and clonality of these malignant cells has been a subject of debate until recently. Because of their scarcity, HRS cells are difficult to study and the molecular basis of their neoplastic phenotype is unknown. However, with the advent of improved techniques for retrieving single cells from pathological specimens and for molecular analysis at the single cell level it has now been established that in more than 96% of examined cases, HRS cells carry clonal and functionally rearranged Ig genes with a high load of somatic mutations (Kuppers and Rajewsky, 1998; Marafioti et al., 2000; Chan, 2001 ). These observations identify HRS cells as clonal outgrowths of a single transformed B cell. Moreover, not only can they be assigned to the B cell lineage on the basis of their Ig gene rearrangements, but their stage of differentiation can also be established because somatically mutated VH genes are specific markers for germinal centre B cells and their descendants. Thus, HRS cells correspond in their developmental stage to germinal or postgerminal centre B cells (Cossman et al., 1999) .
However, the immunophenotype of HRS cells is unusual for cells of B lymphoid origin. They express CD15 and the lymphoid activation gene CD30, but frequently lack common B cell surface markers such as CD19, CD20 and CD79a (mb-1) (Watanabe et al., 2000) . Moreover, HRS cells do not express Ig gene transcripts. Several explanations may account for this lack of marker gene expression: (a) a high load of mutations; (b) deficiency of the transcriptional machinery; and/or (c) epigenetic silencing.
Although karyotypic abnormalities of HRS cells are frequently complex, no recurrent cytogenetic abnormalities have been detected (Kuppers and Rajewsky, 1998; Chan, 2001) . Hence, we find it unlikely that extinction of multiple B cell-specific genes could be due to selective mutagenesis of the respective loci, sparing the genes encoding housekeeping functions. This view is further supported by failure to identify nonfunctional IgL and IgH gene rearrangements or crippling mutations of Ig gene regulatory motifs in the majority of cases of classical HL (Theil et al., 2001) .
Interestingly, regulatory DNA sequences of the eclipsed B cell marker genes share several motifs that bind common B cell-specific transcription factors. During the course of our study, two independent laboratories reported that HRS derived cell lines and most primary HRS cells are devoid of the largely B cell restricted transcription factors Oct-2 and OBF-1 that interact with the octamer motif ATGCAAAT present in all promoters and enhancers of Ig genes and of several other B cell-specific genes (Re et al., 2001; Stein et al., 2001; Theil et al., 2001) . Since this motif is essential for activity of Ig gene promoters, these authors suggested a causative link between absence of these two transcription factors and Ig gene expression. We have largely confirmed lack of Oct-2 and OBF-1 in cell lines and in pathological specimens of classical HL, but several lines of evidence suggest that deficiency of these two transcription factors cannot solely account for loss of Ig gene transcription in HRS cells: (1) Although octamer-dependent reporter constructs including Ig gene promoters may be reactivated in HRS cell lines when cotransfected with Oct-2 and OBF-1 expression plasmids, transcription from endogenous Ig loci is not reactivated (Hertel and Junker, unpublished) ; (2) Ig gene transcription does not strictly require Oct-2 and OBF-1 because B cells derived from knock-out mice engineered to lack functional Oct-2, OBF-1 or both genes produce Igs (Schubart et al., 2001) ; (3) the IgH locus is transcribed in cell lines lacking Oct-2 and OBF-1 (Junker, unpublished) . Thus, these findings imply that the ubiquitous transcription factor Oct-1 together with one or more, as yet unidentified cofactors, plays a more central role in the control of Ig gene transcription than has previously been recognized. Alternatively, Ig gene enhancers rather than Ig gene promoters may be the major determinants of B cell specificity.
Here, we demonstrate that intronic and 3' IgH hs1,2 enhancer sequences are also transcriptionally inactive in HRS cell lines, and that this inactivity correlates with either the loss of, or a significant reduction in levels of transcription factors that are all characteristic of the B cell phenotype: PU.1, PAX-5, E47 and EBF. However, promoter/enhancer sequences of eclipsed B cell surface marker genes can be activated by forced expression of appropriate transcription factors, albeit the endogenous loci remain silent with the exception of one HRS cell line in which transcription of the IgH locus was activated. Interestingly, expression of PU.1 and of PAX-5 is also significantly down-regulated in HRS cells in pathological tissue specimens. Thus, loss Figure 1 The transcriptional capacity of Ig regulatory sequences is severely compromised in Hodgkin lymphoma cell lines. (a) An octamer dependent k light chain promoter is down-regulated in the Hodgkin cell lines L428 and KM-H2. The pkLucE reporter plasmid consists of a 200 bp murine k promoter fragment inserted into the pGL2 enhancer plasmid. In the k0 7 LucE construct the octamer site is mutated. Activity of the luciferase reporter plasmids relative to that of a cotransfected renilla reference plasmid is shown. Error bars indicate the standard deviation from the mean value of three independent experiments. (b) The activity of the human IgH intronic enhancer in the Hodgkin cell lines L428 and KM-H2 is downregulated to levels similar to those in human Jurkat T-cell leukaemia cells. The reporter plasmid pGL2m contains a 260 bp XhoI -BamHI fragment of the IgH intronic core enhancer inserted downstream of the SV40 promoter of the pGL2 promoter vector. The relative activity of luciferase compared to that of a cotransfected renilla reference plasmid is shown. Error bars indicate the standard deviation from the mean value of three independent experiments. (c) The transcriptional capacity of the 3' enhancer is down-regulated in L428 Hodgkin cells. RNase protection assay of cytoplasmic RNA from transfected L428 cells (lanes 1 -3) and Daudi cells (lanes 4 -6). The 1.1 kb StuI -StuI fragment of the rat IgH 3' enhancer drives the transcription of the human b-globin gene in pbG128-3'E (lanes 2 and 5). The plasmid pbG128 includes a 128 bp of 5'-flanking sequence and serves as a negative control, since transcription of its b-globin gene is very weak unless linked to a strong regulatory element (lanes 3 and 6). In the positive control pbG128-SV40, the SV40 enhancer replaces the IgH 3' enhancer (lanes 1 and 4). The constructs were cotransfected with an SV40 enhancer driven expression plasmid encoding the human a-globin gene that serves as an internal control for the efficiency of transfection. In this series of transfections, the human Daudi Burkitt's lymphoma cell line served as a positive control, and the human T cell line Jurkat as a negative control (data not shown) of B cell identity in HRS cells appears, at least in part, to be due to lack of B cell-specific transcription factors required for executing the B lymphoid programme.
Results
The transcriptional activity of Ig regulatory sequences is severely compromised in Hodgkin lymphoma cell lines B cell-specific transcription of Ig genes is determined by interplay of promoter and enhancer sequences binding both ubiquitous and B cell restricted transcription factors (Ernst and Smale, 1995) . By transient transfection assays in the HRS cell lines L428 and KM-H2 we assessed the transcriptional activity of Ig promoter and enhancer sequences individually to establish whether they are targets of the silencing mechanisms. Our results confirm that a murine k light chain gene promoter conferring B cell specificity is transcriptionally inert in the HRS cell line L428 and modestly active in KM-H2 cells (Figure 1a ; for further discussion of the data, cf below). However, by substituting the octamer site with a binding site for the ubiquitously expressed Sp1 transcription factor, this promoter will, in part, gain activity in the HRS L428 cell line, thus identifying the octamer motif as crucial for mediating silencing of the k promoter activity (data not shown).
The IgH locus contains an intronic (Em) and several enhancers 3' of the IgH locus Birshtein et al., 1997) . The intronic enhancer is active throughout B cell development and controls V(D)J recombination. Unlike the intronic enhancer, the IgH hs1,2 3' enhancer is under developmental control being active only in activated B cells and in plasma cell lines of both rodent and human origin. This pattern of activity suggests contributions to multiple events occurring during the late stages of B cell development such as increased transcription, class switching and somatic hypermutation.
To assess the transcriptional activity of these enhancers in Hodgkin cells, reporter constructs driven by enhancer sequences and non-tissue-specific promoters were transiently transfected into the two Hodgkin cell lines L428 and KM-H2, Daudi Burkitt's lymphoma cells (positive control) and human Jurkat T cells (negative control). A 260 bp XhoI -BamHI fragment containing the human IgH intronic core enhancer was inserted down-stream of a luciferase reporter gene, driven by a SV40 promoter. Luciferase activity of this construct transiently transfected into Daudi cells was more than 25-fold higher than that of the enhancerless construct. By contrast, there was hardly any difference in luciferase activity of either construct when transfected into L428, KM-H2 and Jurkat cells (Figure 1b) .
For the analysis of 3' enhancer activity we tested in the same cell lines three constructs containing the human b-globin under the control of (a) a 1.1 kb StuI -StuI fragment of the rat IgH hs1,2 3' enhancer; (b) the ubiquitously active SV40 enhancer fragment replacing the 3' enhancer; and (c) the basic b-globin cassette without enhancer ( Figure 1c ). As expected, SV40 enhancer-driven reporters were highly expressed in all the cell lines. In contrast, the IgH hs1,2 3' enhancer generated b-globin transcripts at levels similar to those of enhancer-less reporters in L428 cells ( Figure  1c ) and in KM-H2 and Jurkat cells (data not shown). Thus, the transcriptional capacity of both the IgH intronic and the hs1,2 3' enhancer is severely compromised in HRS cell lines compared to their activity in Daudi Burkitt's lymphoma cells. Several non-excluding mechanisms may explain this silencing of Ig gene regulatory sequences: negative action of transcriptional repressors, epigenetic silencing, or lack of activity due to loss of essential transcription factors. It is noteworthy that regulatory sequences of Ig genes, and also of other marker genes of the B cell lineage such as CD19 and CD79a that are eclipsed in HRS cells, share functionally important motifs that can bind the same B cell specific transcription factors. Therefore, we examined expression levels in HRS cell lines of six B cell-specific transcription factors that are known to interact with functionally important Ig gene promoter or enhancer motifs: Oct-2, OBF-1, PU.1, E47, PAX-5 and EBF. Targeted inactivation of the genes encoding these transcription factors has revealed that they are also key regulators of B cell development and maturation (for references, cf Singh, 1996) . Since the composition of transcription factors in classical HL cells and in HRS cell lines is still poorly explored, we selected five HRS cell lines that, on the basis of surface markers and of rearrangement of immunoglubulin and T cell receptor genes, are considered to derive from B cells (L428, KM-H2), T cells (L540, HD-LM2) and myeloid-monocytic cells (HD-MyZ) (Table 1) . From each cell line cytoplasmic RNA and extracts of nuclear proteins were simultaneously prepared. Sensitive RNase protection mapping was used to assess steadystate levels of transcripts of transcription factor genes, and electrophoretic mobility shift assay (EMSA) and Western blotting to assess their protein levels. First, we confirm that the B cell-like HRS line L428 is devoid of Oct-2 and OBF-1 specific transcripts, and that this is also true for the T cell-like HRS cell lines L540 and HD-LM2 and for the myelo-monocytic HDMyZ cell line. The sole exception is the B cell-like KM-H2 line in which Oct-2 specific transcripts were detectable although at levels some 10-fold lower than those in Daudi cells, whereas OBF-1 transcripts were absent as in the four other HRS cell lines ( Figure 2a ). This difference in Oct-2 expression may explain the higher activity of the k promoter in KM-H2 cells than that in L428 cells (cf Figure 1a) .
Next we examined PU.1 which binds to the mB element of the IgH intronic enhancer, an element of central importance for enhancer activity as demonstrated by site-directed mutagenesis of that motif (reviewed in Lieberman and Baltimore, 1991). Moreover, PU.1 is required for development of myeloid and lymphoid lineages and is expressed throughout B cell ontogeny (Singh, 1996; Rothenberg, 2000) . In view of its prominent function in the B cell lineage, it came as a surprise to us that none of the HL cell lines, irrespective of their attributed lineages, contained detectable levels of PU.1 transcripts, no matter how long the gels were exposed (Figure 2b ).
Intronic and 3' enhancers of both IgH and Ig k light chain genes contain multiple elements of the E-box class, mutation of any of which significantly reduces enhancer activity (reviewed in Lieberman and Singh and Birshtein, 1993; Neurath et al., 1994) . E12 and E47, that are different splicing products of the E2A gene bind these sites in B cells, although homodimers of E47 appear to be the predominant transcriptionally active form (Bain et al., 1993; Shen and Kadesch, 1995) . To assess nuclear levels of E2A proteins we used Western blotting with an antibody raised against amino acid 1-649 representing full-length E47 protein of human origin ( Figure 3a) . All of the HRS cell lines contained detectable levels of nuclear E47 proteins, although they were at least fivefold lower than the levels found in Daudi cells. Moreover, EMSA employing a mE5 probe revealed that none of the HRS cell lines generated the complex seen only in nuclear extracts of different B cell lines. The complex contains E47 as demonstrated by supershift analyses using polyclonal antisera (Figure 3b ). However, at this stage we cannot rule out that it also contains E12 due to cross-reactivity of commercially available antibodies against E47.
The PAX-5 gene encodes the B cell-specific activator protein (BSAP) which is specifically expressed in the B cell lineage except for the terminally differentiated plasma cells. Its action is bimodal: for example, it regulates transcription from the CD19 promoter positively, but acts negatively in the context of the IgH 3' enhancer (Singh and Birshtein, 1993; Neurath et al., 1994; Pettersson et al., 1997; Nutt et al., 1998; Maitra and Atchison, 2000) . We used RNase protection mapping to assess expression levels of the PAX-5 gene in HRS cell lines relative to levels in Daudi cells (Figure 2c ). In two of the cell lines, L540 and HDMyZ, PAX-5 specific transcripts were not detectable, whereas L428 and KM-H2 generated signals that were at least eight times weaker than those generated from Daudi cells. Remarkably, signals of similar intensity were observed in HD-LM2, despite the fact that the phenotype of this cell line is predominantly T cell-like.
Finally, we analysed the expression profile of early B cell factor (EBF) among the five HRS cell lines. EBF is expressed early in B cell development and is required for execution of the B cell programme. EBF binds to functionally important promoter sites of several B cell specific genes such as CD19, CD79a (mb-1) and the surrogate light chain gene 14.1 (Gisler et al., 1999 (Gisler et al., , 2000 . RNase protection mapping demonstrated very low but significant levels of EBF transcripts in all the cell lines except for HD-MyZ that was devoid of EBF transcripts ( Figure 2c) . As with the finding of PAX-5 transcripts in HD-LM2, the occurrence of EBF transcripts in both HD-LM2 and L540 is remarkable, because these genes have not previously been reported to be expressed in cells with a T cell phenotype.
Transcriptional down-regulation of several B cellrestricted transcription factors in Hodgkin lymphoma cell lines
To determine whether the transcription rate rather than RNA stability explains the lack or the very low steady-state levels of transcripts of B cell-specific transcription factor genes, nuclear run-on transcription assays were performed with nuclei from Daudi cells (positive control), human Jurkat T cells (negative control) and cells of all five Hodgkin's cell lines (Figure 4) . The b-actin gene was used as an internal control. pBR322 and single-stranded Oct-2 sense DNA (M13) served as a negative control. In Daudi cells, transcription was detected of all the B cell-specific genes: IgH(m), Oct-2, OBF-1, PU.1, PAX-5 and EBF. The same nuclear extracts were analysed by EMSA for the binding of E-box proteins to a mE5 probe. The B cell line-specific complex formed only in the Daudi cell line is not affected in supershifts assays using antibodies against HEB or E2-2. However, the complex is completely abolished with an antibody against E47, but also with commercially available E12 antibodies possibly because of their cross-reactivity with E47 (data not shown)
In Jurkat cells, the signals generated of the same genes were hardly above those of the negative controls with the exception of OBF-1. We ascribe that relatively strong signal to intrinsic properties of the probes, because similarly strong signals are generated from other non-B cells like Hela cells and fibroblasts (unpublished data). We also believe that the PU.1 signals generated in the Hodgkin samples are due to unspecific annealing. However, by and large, data from the run-on assays mirror RNA expression levels of the transcription factor genes, thus demonstrating that the genes are down-regulated at the level of transcription.
Expression of B cell transcription factors PU.1 and PAX-5 is down-regulated in primary HRS cells in classical HL
Although gene expression profiles most often are similar in tumours and in cell lines derived thereof, there, nevertheless, remains the possibility, that the unusual expression profile of B cell-specific transcription factors in HRS cell lines could be ascribed to a culture artefact. Therefore, we extended our analyses to pathological specimens that were immunostained with relevant mono-specific antibodies. For technical reasons we were unable to perform conclusive analyses regarding EBF and E47. Regarding Oct-2 we confirm a previous report (Re et al., 2001 ) that this transcription factor is not expressed in the majority of cases of classical HL (data not shown).
To establish specificity and sensitivity of the PU.1 and PAX-5 monclonal antibodies, respectively, immunohistological staining of control tissues was performed. Both antibodies gave reproducible and appropriate reactions. Moderately strong PU.1 nuclear expression was seen in lymphocytes in B cell areas of reactive lymph node (particularly in mantle cells) and in some histiocytes. Strong nuclear labelling of germinal centre and mantle zone B-cells was seen with anti-PAX-5. Tumour cells in a case of nodal small lymphocytic lymphoma/chronic lymphocytic leukaemia gave strong diffuse nuclear staining for both PU.1 and PAX-5.
Eighteen cases of classical HL (13 nodular sclerosis and five mixed cellularity subtypes) were examined for expression of PU.1 and PAX-5 (Table 2 ). HRS cells in classical HL were consistently negative for PU.1 in spite of adequate controls. In all cases, reactive B cells acted as additional (internal) positive controls ( Figure  5a ). HRS cells in 13 of 18 HL cases (72%) showed nuclear labelling with anti-PAX-5. There was considerable variation in the estimated percentage of positive HRS cells in these tumours, only four cases showing expression in more than half the HRS cells, these being the only ones to show moderate or strong staining. Overall, the PAX-5 expression was either weak (Figure 5b ), or entirely absent in HRS cells in 14 HL cases (78%). There was no correlation between infection with EBV and the results of PU.1 and PAX-5 staining.
Taken together, our data strongly suggest that lack of expression of B cell marker genes including Ig, CD19 and CD79a in HRS cells and HRS-derived cell lines is, at least in part, due to critically reduced levels or, in some cases, complete loss of B cell specific transcription factors required for their expression.
Silenced regulatory sequences of B cell specific genes can be activated in HRS cell lines by forced expression of relevant transcription factors Although our findings suggest a causative link between deficiency of B cell-specific transcriptional machinery and silenced transcription of B cell specific genes in LucE construct the octamer site is mutated. Activity of the luciferase reporter plasmids relative to that of a cotransfected renilla reference plasmid is shown. (b) Co-transfection of PU.1 expression plasmid in KM-H2 cells activates transcription from a luciferase reporter construct containing three PU.1 binding sites upstream of the HSV thymidine kinase minimal promoter. The activity obtained with this reporter and the reporters in c-f in the absence of ectopically expressed transcription factors is arbitrarily set to 1. (c) A luciferase reporter gene under the control of a minimal c-fos promoter driven by three copies of the mE2-E5 binding site of the IgH intronic enhancer is activated upon expression of forced E47 homodimers in L428 cells. fos-LucE serves as a control since transcription from the c-fos promoter on its own is very weak unless linked to a strong regulatory element. The activity of the mE2E5 reporter is 46 -60 times higher in Daudi cells than in L428 cells. (d) The human CD79a (mb-1) promoter is activated some eightfold upon co-transfection with expression vector encoding EBF. In Daudi cells, activity of the mb-1 promoter is 12 -16 times higher than that in KM-H2 cells. (e) The luciferase reporter gene under the control of the B cell-specific CD19 promoter is reactivated upon co-transfection with expression vectors encoding PAX-5 and EBF in KM-H2 cells. CD19 promoter activity is 13 -20 times higher in Daudi cells than in KM-H2 cells. (f) The B cell-specific 14.1 promoter controlling transcription of the luciferase reporter is reactivated by ectopic expression of EBF and of forced homodimers of E47. EBF on its own stimulates this promoter some fourfold whereas EBF co-expressed with E47 results in a sevenfold increase in promoter activity. Compared to the activity of this promoter in L428 cells, its activity in Daudi cells is 17 -23 times higher. In all transfection experiments the relative activity of the luciferase reporter plasmids is shown compared with that of a cotransfected renilla reference plasmid be transcribed. Moreover, in the light of the autoregulatory role of PU.1 (Chen et al., 1995) , and the post-translational down-regulation of e.g. OBF-1 protein levels by Siah-1 (Tiedt et al., 2001; Boehm et al., 2001) , it is also possible that one or more of these transcription factors, had they been produced in HRS cells, would have been specifically targeted for degradation.
To address this we transiently cotransfected into both HRS cell lines of the B cell type expression plasmids encoding relevant transcription factors together with reporter genes under the control of regulatory sequences (promoter and/or enhancer fragments) of genes encoding Igs, CD19, CD79a and 14.1. In parallel, attempts were made to restore transcription from corresponding endogenous loci by forced expression of one or more transcription factors. Reporter genes were also transfected into Daudi and Jurkat cells, serving as positive and negative controls, respectively.
As described, an octamer-dependent k light chain gene promoter is transcriptionally inactive in HRS cells. However cotransfection with expression plasmids encoding Oct-2 and/or OBF-1 stimulated luciferase activity up to eightfold (Figure 6a ) thus demonstrating that promoter inactivity is due to lack of these transcription factors.
We tested the transcriptional potential of PU.1 by cotransfection with a reporter construct containing three PU.1 binding sites upstream of the HSV thymidine kinase minimal promoter. As shown in Figure 6b , PU.1 elevated transcription from that reporter some 25-fold but it was not sufficient on its own to induce transcription from either the endogenous IgH locus or from a reporter driven by a 700 bp core fragment of the intronic heavy-chain enhancer (data not shown).
Ectopic expression of forced homodimers of E47 substantially increased luciferase activity from a reporter construct consisting of three copies of the mE2-E5 fragment of the IgH intronic enhancer ( Figure  6c) . Interestingly, the HD-LM2 cell line with a T celllike phenotype generates Cm transcripts from the unrearranged IgH locus at extremely low levels. Transient E47 expression in these cells resulted in at least a 20-fold increase in steady-state levels of Cm transcripts (Figure 7) . However, Cm transcripts from the endogenous IgH locus were never detected in any of the four other HRS cell lines.
The human CD79a (mb-1) promoter contains a single EBF binding site that could be activated eightfold by EBF in e.g. KM-H2 cells (Figure 6d) .
The human CD19 promoter is a target for both EBF and BSAP (Nutt et al., 1998; Gisler et al., 1999) . In KM-H2 cells, EBF on its own resulted in a threefold increase in promoter activity, BSAP on its own in some fivefold increase, and when both factors were coexpressed, promoter activity was elevated some fivefold ( Figure 6e) . Nevertheless, irrespective of our experimental conditions, the endogenous CD19 locus was not activated as monitored by FACS analysis (data not shown).
Finally, the promoter for the 14.1 surrogate light chain gene can be activated by the concerted action of EBF and E47 in non-B cells. In L428 cells, forced expression of EBF or coexpression with E47 induced the 14.1 promoter some five-and sevenfold, respectively, whereas E47 on its own was without any effect (Figure 6f) .
Thus, our data demonstrate that a number of ectopically expressed B cell-specific transcription factors are indeed functionally active in HRS cell lines and can induce both engineered and natural B cellspecific promoters and enhancers of extinguished B cell marker genes. However, when tested under the aforementioned conditions, they are generally not sufficient to transactivate extinguished homologous endogenous loci, indicating that additional mechanisms contribute to B cell-specific gene silencing.
Discussion
HRS cells in classical HL are generally regarded as clonal derivatives of germinal center B cells because the vast majority of HRS cells carry rearranged Ig genes with a high load of somatic hypermutation (Kuppers and Rajewsky, 1998; Marafioti et al., 2000; Chan, 2001) . Nevertheless, these cells do not produce Ig gene transcripts, nor do they express a number of surface markers characteristic of B cells, including CD19. Thus, although HRS cells carry permanent genomic prints of their origin, they appear to have lost their B cell identity through globally acting mechanism(s) that selectively extinguish the B cell phenotype. Figure 7 Expression of forced E47 homodimers trans-activates transcription from the endogenous IgH locus in the Hodgkin cell line HD-LM2 but not in the cell lines L428 and KM-H2. RNase protection assay, using a Cm-specific probe, of 10 mg of cytoplasmic RNA isolated from transiently transfected and non-transfected Hodgkin cell lines and from Daudi Burkitt's lymphoma cells
In the present paper we demonstrate that extinction of Ig gene transcription in HRS cell lines with a B cell phenotype correlates with lack of activity of Ig promoters and of intronic and hs1,2 3' enhancer sequences as tested in transient transfection assays. Moreover, this inactivity is associated with greatly reduced levels or even loss of several B cell-restricted transcription factors that bind sequence motifs within these regulatory regions: Oct-2, OBF-1, PU.1, E47/ E12, PAX-5 and EBF. Using nuclear run-on assays, we demonstrate that most of the genes encoding these transcription factors are silenced at the level of transcription. Similarly, expression deficiencies are also observed by immunohistology in HRS cells in primary tumour tissue of classical HL. Thus, in HRS cells in most HL cases, Oct-2 was absent (data not shown), PAX-5 was expressed at low levels if at all, and PU.1 was not detectable. The compromised B cell-specific transcriptional machinery also affects the expression of additional B cell marker genes eclipsed in HRS cells, because reporter genes driven by promoter or enhancer segments of CD19, 14.1, CD79a, or Ig genes were stimulated when cotransfected with expression plasmids encoding the relevant B cell-restricted transcription factors missing in HRS cells. It is, therefore, reasonable to conclude that our findings in HRS cell lines mirror events occurring also in primary HRS cells in HL, and that the unusual immunophenotype of these cells reflects a seriously compromised B cell-specific transcription machinery.
It should, however, be emphasized that transient introduction of one or several of the eclipsed transcription factors into different HRS cell lines was insufficient to activate transcription from endogenous Ig or CD19 loci, with one exception. In the HD-LM2 cell line with a predominant T cell phenotype, forced expression of E47 caused substantial upregulation of Cm transcripts from the non-rearranged IgH locus. However, unlike the other HRS cell lines, very low signals of Cm transcripts were already present in the HD-LM2 cells prior to transfection. Our findings, therefore, confirm that forced expression of E47 in non-B cells can induce transcription from unrearranged IgH loci that are primed for transcription (Schlissel et al., 1991; Choi et al., 1996) .
Taken together, our data show that the silencing of B cell-specific genes encoding Igs and surface markers such as CD19 and CD79a in HRS cell lines and in HRS cells is, at least in part, due to lack of essential transcription factors. However, failure to reactivate these genes by transient reconstitution with some of the missing transcription factors, indicates that additional factors and/or mechanisms contribute to the global silencing of the B cell phenotype.
During the course of our studies two independent laboratories reported a correlation between Ig promoter inactivity and absence of Oct-2 and OBF-1 in HRS cell lines (Theil et al., 2001; Re et al., 2001; Stein et al., 2001) . Moreover, in agreement with our findings, they were unable to detect Oct-2 and OBF-1 in the majority of primary HRS cells. In addition to Oct-2 and OBF-1, the only other B cell-specific transcription factor that has previously been examined in HRS cells or HRS cell lines is PAX-5 (Hsu et al., 1996; Krenacs et al., 1998; Foss et al., 1999) . The immunohistological data are, however, conflicting. In the light of the central importance of this transcription factor for maintaining B cell identity but also for preventing B cells from embarking on any non-B lineage developmental programme (Nutt et al., 1999; Horcher et al., 2001) and also of its cellular concentration (Wallin et al., 1998) , we assessed PAX-5 expression semi-quantitatively in HRS cells from primary pathological tissues. Using immunohistology, we found expression of PAX-5 in HRS cells in 13/18 (72%) cases of classical HL. Our overall result is comparable to the findings of Foss et al. (1999) who detected PAX-5 in HRS cells in some 90% of HL cases using the same monoclonal antibody clone. However, in our hands expression was often only seen in a minority of HRS cells and was in general weak compared to expression in control B cells, a result which more closely resembles the findings of Krenacs et al. (1998) . Thus we conclude that in the majority of HRS cells of classical HL and in HRS cell lines, PAX-5 is expressed either at low levels or not at all, providing a possible explanation for loss of, e.g. CD19 expression, but also for the frequently observed expression of the myeloid-monocytic surface marker CD15 in primary HRS cells (Rudiger et al., 1998) and in HRS cells lines irrespective of their predominant phenotype (see Drexler, 2001) . In fact the occurrence of CD15 in cHL has previously contributed to the confusion over the cellular origin of HRS cells.
Interestingly, the transcription factors examined in the present study are important not only for the transcriptional regulation of B cell marker genes, but apparently also as part of a hierarchy of transcription factors, regulating B cell development (Singh, 1996; Rothenberg, 2000) . Thus, PU.1, which is probably autoregulated (Chen et al., 1995) , is required for the development of B and T cells as well as several myeloid cell types (Scott et al., 1994) . E47 and EBF are required for specification of the B cell lineage (for references, cf Singh, 1996) and they also act by turning on additional transcription factor genes that help them execute the B lineage programme: Overexpression of E47 turns on EBF (Kee and Murre, 1998) , and together these two transcription factors turn on PAX-5 (O'Riordan and Grosschedl, 1999) . Dedifferentiation of HRS cells may very well reflect an interference with such a transcriptional hierarchy. In this context, it would be interesting to reconstitute stable high expression levels of E47 and EBF or their downstream target PAX-5 in HRS cell lines in order to determine the extent to which the B cell programme might be restored.
What initiates silencing of these transcription factor genes and how is it stabilized? Several mechanisms may be considered. Resetting the gene expression status of differentiated B cells could be mediated through a repressor such as msx1. When this transcription factor is overexpressed in mammalian myotubes, these terminally differentiated cells revert to a dedifferentiated phenotype. Moreover, they can subsequently be induced to redifferentiate into cells expressing chondrogenic, adipogenic, myogenic and/or osteogenic markers (Odelberg et al., 2000) . Although highly speculative, the existence of such a repressor would be compatible with the promiscuous low expression of e.g. EBF and PAX-5 in the HRS cell lines L540 and HD-LM2 despite their predominant T cell phenotype.
It is now well established that modification of nucleosome structure is an important regulatory mechanism of gene transcription. Two major classes have been identified, both of which have been implicated in development of cancer. The first class consists of histone acetyltransferases (HAT) and deacetylase complexes, which, respectively add or remove acetyl groups from the amino termini of the four histones (reviewed in Jenuwein and Allis, 2001). The second class consists of ATP-dependent chromatin remodelling complexes which alter chromatin structure by changing the location or conformation of the nucleosome (reviewed in Kingston and Narlikar, 1999; Klochendler-Yeivin et al., 2002) . Recent work has demonstrated a high degree of specificity of the composition of such complexes in activating gene transcription (Lemon et al., 2001) . In the light of a recent report on the requirement of SWI/SNF complexes for activation of a whole set of musclespecific transcription factor genes during induction of muscle-specific differentiation of NIH3T3 fibroblasts (de la Serna et al, 2001a,b) , it could be envisaged that imbalance of the composition of a putative complex dictating B cell specificity would have global effects on the B cell phenotype.
Recent studies suggest that genes that are specifically silenced during lymphocyte differentiation are recruited to centromeric heterochromatin compartments when they are repressed (Brown et al., 1997) . These transcriptionally inactive genes co-localize with the lymphoid-restricted transcription factor Ikaros, suggesting that Ikaros proteins which bind to the regulatory regions of several lymphoid-specific genes, might specifically recruit them to heterochromatic centers (Brown et al., 1997 (Brown et al., , 1999 . These centres may act as a place where transcriptional inactivation of genes is established and maintained through epigenetic mechanisms such as deacetylation of histones (Jenuwein and Allis, 2001) and methylation of e.g. promoter sequences, common mechanisms in cancers as means of downregulating key regulators (Jones and Laird, 1999) .
Thus, in HRS cells, B cell-specific master regulators might be mislocated to regions close to centromeric heterochromatin and silenced by the spreading of heterochromatin, a mechanism that is attractive in the light of reports linking mutations in Ikaros to human leukaemias (Sun et al., 1999a,b) . It would, therefore, be of interest to establish the subnuclear localization of some of the extinguished transcription factor genes (and their target genes) and Ikaros in both primary HRS cells and HRS-derived cell lines, and to monitor whether forced expression of e.g. PU.1 or PAX-5 influences their nuclear localization. Such studies together with treatment of HRS cells with inhibitors of histone deacetylases and methyltransferases might provide insights into the mechanism(s) of global but selective down-regulation of the B cell programme in HRS cells.
Materials and methods

Cell culture and cell lines
All cell lines were grown in RPMI 1640 supplemented with 10% foetal calf serum, L-glutamine and antibiotics. The Daudi human Burkitt's lymphoma and the Jurkat T cell lines served as positive and negative controls, respectively. The HL-derived cell lines L428 and KMH2 are of B cell type, while L540 and HDLM2 represent predominantly T cell types. HD-MyZ is a Hodgkin-derived cell line with myelomonocytic features. For further details on phenotypic characteristics of the cell lines and references to their origin, cf Drexler (2001) . The Hodgkin cell lines were purchased from German Collection of Micro-organisms and Cell Cultures, Braunschweig, Germany.
Transfection and reporter gene assays
Cells were transfected using DEAE-dextran as described earlier (Junker et al., 1990) . For luciferase assays, 2 mg of reporter plasmids, 40 ng of renilla reference plasmids and various amounts of expression vector DNA (from 0.5 -2.0 mg). Whole cell extracts were prepared 40 -48 h after transfection using dual-luciferase kit (Promega) and firefly luciferase activity relative to that of renilla luciferase was determined according to the manufacturers' instructions (Promega). At least two independent transfections were made with each construct. Relative transfection efficiencies of cell lines, estimated on the basis of renilla luciferase activity per 100 mg protein, were on average: Daudi 12000 RLU; Jurkat 10000 RLU; L428 5800 RLU; KM-H2 3500 RLU. A 260 bp BamH1 -Xho1 fragment of the human IgH intronic enhancer, containing three mE motifs (mE1, mE2, mE4) and the mA, mC, mB, and OCTA motifs, was inserted down-stream of the SV40 promoter of the pGL2 promoter vector (Pedersen, unpublished) . To assess activity of the rat IgH hs1,2 3'enhancer, we used the constructs pbG128-3'E (Grant et al., 1992) , pbG128 and pbG128-SV40 (Weston, 1988) and RNase protection mapping protocol as described in Andersen et al. (1997) . The reporter plasmids pKappaLucE (wild-type murine k promoter) and pKappa0 -LucE (mutated octamer site) are described in Strubin et al. (1995) . The 14.1 and mb-1 promoter-controlled luciferase reporters are described in Gisler et al. (2000) and the CD19 promoter-controlled reporter in Gisler et al. (1999) . 3*PU.1-Luc is from Nerlov and Graf (1998) . Expression vectors encoding human transcription factors were provided by P Matthias (Oct-2 and OBF-1), M Sigvardsson (PU.1, EBF, E47), and M Buslinger (PAX-5).
Protein extracts, electrophoretic mobility shift assays, and Western blotting Nuclear extracts were prepared according to Schreiber et al. (1989) and protein concentrations were determined by Bradford reagent (Bio-Rad). DNA probes were 32 P-labelled with T4 kinase or Klenow enzyme and purified on 5% polyacrylamide gels. As described earlier 2 -5 mg nuclear extracts were incubated and separated on 6% polyacrylamide gels, which were dried and subjected to autoradiography. For supershift assays 1 ml of the relevant antibody was added 30 min prior to addition of probe.
Western blotting was used to assess expression levels of transcription factors in HL-derived cell lines. Thirty mg of nuclear extracts were separated on 12% sodium dodecyl sulfate-polyacrylamide gels; proteins were transferred to polyvinylidene difluoride (PVDF) membranes by electro blotting and incubated with relevant antibodies. After incubation with an appropriate secondary antibody, the blots were developed using enhanced chemiluminescence detection system (Amersham). The following polyclonal antibodies from Santa-Cruz were used: E47 (N-584), E12 (H-208) and HEB (A-20) . From Pharmingen was purchased anti-human E2-2 (14791A).
RNA analysis
Cytoplasmic RNA was prepared and RNase protection assays were carried out as described . In brief, gel-purified radio labeled cRNA probes were hybridized with 10 mg of cytoplasmic RNA at 458C overnight. After RNase digestion, RNA was resolved on a 5% polyacrylamide gel and autoradiographed. The probes used for analysis of transcripts of Cm, g-actin, Oct-2 and OBF-1 has been described in Junker et al. (1997) . For mapping EBF transcripts, a probe, generating a protected fragment of approximately 180 nt was used. The probe was provided by M Sigvardsson. M Busslinger provided us with a PAX-5 specific probe that produces a protected fragment of approximately 300 nt. Sola Kim prepared the human PU.1 probe that generates a protected fragment of 293 nt.
Nuclear run-on transcription assays
Transcription rate assays were done essentially as described previously except that Cot-1 DNA was included in the hybridization mixture to block unspecific annealing. In addition to the probes used, we included human cDNA encoding approximately 3 kb of EBF (hEBF cDNA, M Sigvardsson), 3.3 kb of PAX-5 (phBSAP-1s, M Busslinger), and 2.8 kb of PU.1 (pKSPU.1cDNA).
Tissues
Eighteen cases of classical type HL from Danish patients (five cases mixed cellularity HL; 13 cases nodular sclerosis HL) were selected from the archives of the Institutes of Pathology, Aarhus University Hospital. Histological diagnosis and subtyping of HL was based on widely accepted morphological and immunophenotypical criteria (Jaffe et al., 2001) . All cases had been examined for the presence of Epstein-Barr virus (EBV) sequences using EBV-encoded small RNA (EBER) in situ hybridization (data not shown). In addition, two tonsils and three lymph nodes showing benign reactive lymphoid hyperplasia, and a lymph node involved by small lymphocytic lymphoma/chronic lymphocytic leukaemia were included as controls for immunohistology. All tissues had been routinely fixed in formalin and embedded in paraffin.
Immunohistochemistry
The monoclonal anti-human PU.1 antibody (clone G148-74) was from BD Pharmingen (San Diego, CA, USA), mouse anti-Pax-5 (clone 24) from BD Transduction Laboratories (Lexington, KY, USA), and polyclonal anti-Oct-2 antibody (C-20) from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Formalin-fixed and paraffin-embedded tissues were cut at 4 mm onto silanized slides. Primary monoclonal antibody incubation (dilution 1 : 10) was performed for 30 min following antigen retrieval by microwave superheating in TEG buffer (10 mM TRIS, 0.5 mM EGTA) at pH 9.0. Sections were stained using the EnVison TM horseradish peroxidase system (DAKO, Glostrup, Denmark) and developed in diaminobenzidine. The percentage of positive HRS cells was assessed semiquantitatively, and the strength of staining designated: 0 (no staining); 1+, 2+, or 3+ (weak, moderate, or strong staining).
